BRAIN Biotech AG Releases H1 Financials and Maintains Full-Year Forecast

BRAIN Biotech AG, a key player in enzyme and biosolutions for industry, published its half-year results for fiscal 2025/26, reporting revenues of €23.4 million, a 7.2% decrease from the previous year. The BRAINBiocatalysts segment faced challenges, notably weak sales in bakery enzymes and production disruption due to facility relocation. Despite this, the adjusted consolidated EBITDA improved, nearing break-even at €-0.1 million, compared to €-1.1 million the previous year.

The firm announced a granted European patent for its BMC® genome editing technology, reflecting promising advancements in the BRAINBioIncubator sector. This segment's revenues increased to €3.0 million, aided by a significant milestone payment from a key project. The group anticipates stable revenue and an adjusted EBITDA margin of around 10% for its core segment, amid economic uncertainties.